SCHEMBL5467883

SCHEMBL5467883

COc1ccc(C(=O)Nc2ccc3[nH]c4c(c3c2)CCCC4NC2CCCCC2)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SIRT1 Q96EB6 1/20 0.48
▸ RB1 P06400 5/20 0.48
▸ MAPT P10636 5/20 0.47
▸ TP53 P04637 3/20 0.47
▸ KDM4E B2RXH2 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.43
▸ POLB P06746 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPKAPK2 P49137 2/20 0.42
▸ BRD3 Q15059 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460533 0.84 RB1 (0.52) SIRT1RB1MAPTKDM4ENPC1
SCHEMBL5452147 0.80 RB1 (0.57) RB1MAPTTP53NPC1RAB9A
SCHEMBL5460625 0.79 SIRT1 (0.53) SIRT1MAPTKMT2AMEN1SMN1; SMN2
SCHEMBL5449914 0.79 RB1 (0.56) SIRT1RB1MAPTKMT2AMEN1
SCHEMBL5456655 0.79 RB1 (0.56) RB1MAPTTP53KMT2AMEN1
SCHEMBL5460471 0.78 RB1 (0.58) SIRT1RB1MAPTKMT2AMEN1
SCHEMBL5466568 0.78 RB1 (0.58) SIRT1RB1MAPTKMT2AMEN1
SCHEMBL5461886 0.78 RB1 (0.53) RB1MAPTNPC1RAB9AKMT2A
SCHEMBL5468135 0.78 RB1 (0.55) RB1MAPTTP53KMT2AMEN1
SCHEMBL5445869 0.78 RB1 (0.57) SIRT1RB1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 — — US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 — — US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276009-A1 Compositions and Methods for Viral Inhibition MAVS, SARS1, ZC3HAV1 SIRT1 4589/4885RB1 1821/4885MAPT 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback